Charles Schwab Investment Management Inc. Increases Stake in Astrana Health, Inc. (NASDAQ:ASTH)

Charles Schwab Investment Management Inc. lifted its stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 5.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 471,329 shares of the company’s stock after acquiring an additional 23,533 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Astrana Health were worth $14,861,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. KBC Group NV purchased a new position in shares of Astrana Health during the 3rd quarter worth about $70,000. Quarry LP purchased a new position in shares of Astrana Health during the 3rd quarter worth about $77,000. Quest Partners LLC purchased a new position in shares of Astrana Health during the 3rd quarter worth about $133,000. Paloma Partners Management Co purchased a new position in shares of Astrana Health during the 3rd quarter worth about $220,000. Finally, Quantbot Technologies LP purchased a new position in shares of Astrana Health during the 3rd quarter worth about $244,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Stock Down 2.2 %

Shares of NASDAQ:ASTH opened at $30.82 on Friday. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health, Inc. has a 52-week low of $23.12 and a 52-week high of $63.20. The company has a 50 day moving average of $33.95 and a two-hundred day moving average of $42.67. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. As a group, analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on ASTH. Bank of America dropped their target price on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Truist Financial dropped their target price on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a research report on Tuesday. Macquarie raised shares of Astrana Health to a “hold” rating in a research report on Monday, December 16th. Robert W. Baird dropped their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. Finally, Stifel Nicolaus dropped their target price on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.17.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.